1. Apicella C, Ruano CSM, Méhats C, Miralles F, Vaiman D. The role of epigenetics in placental development and the etiology of preeclampsia. Int J Mol Sci 2019; 20: 2837.
2.
Barrios V, Chowen JA, Martín-Rivada Á, Guerra-Cantera S, Pozo J, Yakar S, Rosenfeld RG, Pérez-Jurado LA, Suárez J, Argente J. Pregnancy-associated plasma protein (PAPP)-A2 in physiology and disease. Cells 2021; 10: 3576.
3.
Belovic DK, Plešinac S, Dotlić J, Radojević AS, Akšam S, Cvjetićanin MM, Kocijančić A. Biochemical markers for prediction of hypertensive disorders of pregnancy. J Med Biochem 2019; 38: 71-82.
4.
Bunyapipat P, Pruksanusak N, Suwanrath C, Geater A. Combined maternal risk factors and the Quadruple test to predict late-onset preeclampsia in pregnant Thai women. BMC Pregnancy Childbirth 2023; 23: 277.
5.
Caliskan R, Atis A, Aydin Y, Acar D, Kiyak H, Topbas F. PAPP-A concentrations change in patients with gestational diabetes. J Obstet Gynaecol 2020; 40: 190-194.
6.
Chen Y, Chen Y, Shi Y, Ning W, Wang X, Li L, Zhang H. External quality assessment of maternal serum levels of alpha-fetoprotein, free beta-human chorionic gonadotropin, and unconjugated estriol in detecting Down syndrome and neural tube defects in the second trimester of 87 maternal serum samples, based on 105-139 days. Med Sci Monit 2022; 28: e935573.
7.
Conover CA. Role of PAPP-A in aging and age-related disease. Exp Gerontol 2013; 48: 612-613.
8.
Dinglas C, Afsar N, Cochrane E, Davis J, Kim S, Akerman M, Wells M, Chavez M, Herrera K, Heo H, Vintzileos A. First-trimester maternal serum alpha fetoprotein is associated with ischemic placental disease. Am J Obstet Gynecol 2020; 222: 499.e1-499.e6.
9.
Hauspurg A, Jeyabalan A. Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy. Am J Obstet Gynecol 2022; 226: S1211-S1221.
10.
Hughes AE, Sovio U, Gaccioli F, Cook E, Charnock-Jones DS, Smith GCS. The association between first trimester AFP to PAPP-A ratio and placentally-related adverse pregnancy outcome. Placenta 2019; 81: 25-31.
11.
Ives CW, Sinkey R, Rajapreyar I, Tita ATN, Oparil S. Preeclampsia-pathophysiology and clinical presentations: JACC state-of-the-art review. J Am Coll Cardiol 2020; 76: 1690-1702.
12.
Johnsson VL, Pedersen NG, Worda K, Krampl-Bettelheim E, Skibsted L, Hinterberger S, Strobl I, Bowman ME, Smith R, Tabor A, Rode L. Plasma progesterone, estradiol, and unconjugated estriol concentrations in twin pregnancies: Relation with cervical length and preterm delivery. Acta Obstet Gynecol Scand 2019; 98: 86-94.
13.
Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, Gotsch F, Erez O. The etiology of preeclampsia. Am J Obstet Gynecol 2022; 226: S844-S866.
14.
MacDonald TM, Walker SP, Hannan NJ, Tong S, Kaitu’u-Lino TJ. Clinical tools and biomarkers to predict preeclampsia. EBioMedicine 2022; 75: 103780.
15.
Meng ML, Frere Z, Fuller M, Li YJ, Habib AS, Federspiel JJ, Wheeler SM, Gilner JB, Shah SH, Ohnuma T, Raghunathan K, Krishnamoorthy V. Maternal cardiovascular morbidity events following preeclampsia: A retrospective cohort study. Anesth Analg 2023; 136: 728-737.
16.
Michalczyk M, Celewicz A, Celewicz M, Woźniakowska-Gondek P, Rzepka R. The role of inflammation in the pathogenesis of preeclampsia. Mediators Inflamm 2020; 2020: 3864941.
17.
Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet 2016; 387: 999-1011.
18.
Orosz L, Orosz G, Veress L, Dosa D, Orosz Sr L, Arany I, Fabian A, Medve L, Pap K, Karanyi Z, Toth Z, Poka R, Gabor Than N, Torok O. Screening for preeclampsia in the first trimester of pregnancy in routine clinical practice in Hungary. J Biotechnol 2019; 300: 11-19.
19.
Papamichail M, Fasoulakis Z, Daskalakis G, Theodora M, Rodolakis A, Antsaklis P. Importance of low pregnancy associated plasma protein-A (PAPP-A) levels during the first trimester as a predicting factor for adverse pregnancy outcomes: A prospective cohort study of 2636 pregnant women. Cureus 2022; 14: e31256.
20.
Phipps EA, Thadhani R, Benzing T, Karumanchi SA. Pre-eclampsia: pathogenesis, novel diagnostics and therapies. Nat Rev Nephrol 2019; 15: 275-289.
21.
Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: Pathophysiology, challenges, and perspectives. Circ Res 2019; 124: 1094-1112.
22.
Vasciaveo L, Rizzo G, Khalil A, Alameddine S, Di Girolamo R, Candia M, De Lucia G, Mappa I, Liberati M, Nappi L, D’Antonio F. Assessment of pericallosal artery at 11-14 weeks of gestation: Cohort study and meta-analysis. J Clin Ultrasound 2022; 50: 984-988.
23.
Wyness SP, Snow TM, Villanueva M, Kunzler T, Seiter J, Genzen JR, Johnson LM. Impact of unconjugated estriol (uE3) assay interference on prenatal screening tests. Clin Chim Acta 2022; 536: 1-5.
24.
Yang Y, Le Ray I, Zhu J, Zhang J, Hua J, Reilly M. Preeclampsia prevalence, risk factors, and pregnancy outcomes in Sweden and China. JAMA Netw Open 2021; 4: e218401.
25.
Younesi S, Mahdi Taheri Amin M, Saadati P, Yazdani B, Jamali S, Modarresi MH, Savad S, Amidi S, Ghafouri-Fard S, Razmpoosh E, Yazarlou F. Fine-tuning of routine combined first-trimester screening: The ratio of serum-free-beta-human chorionic gonadotropin (fb-hCG) to pregnancy-associated plasma protein-A (PAPP-A) could improve performance of Down syndrome screening program, a retrospective cohort study in Iran. Hum Antibodies 2020; 28: 203-210.
26.
Zhang W, Liang H. The role of serum markers PAPP-A b-hCG, AFP, and uE3 in predicting the risk of preeclampsia in early, middle, and late pregnancy. Technol Health Care 2023; 31: 1027-1037.
27.
Ziolkowska K, Dydowicz P, Sobkowski M, Tobola-Wrobel K, Wysocka E, Pietryga M. The clinical usefulness of biochemical (free b-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy. Ginekol Pol 2019; 90: 161-166.
